
Michael D. Burkhart
Examiner (ID: 3350, Phone: (571)272-2915 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1636, 1638, 1633 |
| Total Applications | 1174 |
| Issued Applications | 608 |
| Pending Applications | 127 |
| Abandoned Applications | 453 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14563803
[patent_doc_number] => 20190209508
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-11
[patent_title] => COMPOSITIONS AND METHODS FOR CONTROLLING INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 16/357964
[patent_app_country] => US
[patent_app_date] => 2019-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7113
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16357964
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/357964 | COMPOSITIONS AND METHODS FOR CONTROLLING INFECTIONS | Mar 18, 2019 | Abandoned |
Array
(
[id] => 14567017
[patent_doc_number] => 20190211115
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-11
[patent_title] => METHODS FOR PRODUCING FABS AND BI-SPECIFIC ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/298113
[patent_app_country] => US
[patent_app_date] => 2019-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25793
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298113
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/298113 | Methods for producing Fabs and bi-specific antibodies | Mar 10, 2019 | Issued |
Array
(
[id] => 16771115
[patent_doc_number] => 10982210
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Compositions for delivery of cargo to cells
[patent_app_type] => utility
[patent_app_number] => 16/290348
[patent_app_country] => US
[patent_app_date] => 2019-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 13
[patent_no_of_words] => 16320
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16290348
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/290348 | Compositions for delivery of cargo to cells | Feb 28, 2019 | Issued |
Array
(
[id] => 17728010
[patent_doc_number] => 11384388
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-12
[patent_title] => DNA vaccines
[patent_app_type] => utility
[patent_app_number] => 16/265919
[patent_app_country] => US
[patent_app_date] => 2019-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 14581
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265919
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/265919 | DNA vaccines | Jan 31, 2019 | Issued |
Array
(
[id] => 14338931
[patent_doc_number] => 20190151438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-23
[patent_title] => VACCINATION WITH mRNA-CODED ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 16/264073
[patent_app_country] => US
[patent_app_date] => 2019-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32682
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16264073
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/264073 | VACCINATION WITH mRNA-CODED ANTIGENS | Jan 30, 2019 | Abandoned |
Array
(
[id] => 16126015
[patent_doc_number] => 10696750
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-30
[patent_title] => Multi-specific monoclonal antibodies
[patent_app_type] => utility
[patent_app_number] => 16/264028
[patent_app_country] => US
[patent_app_date] => 2019-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 19372
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 372
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16264028
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/264028 | Multi-specific monoclonal antibodies | Jan 30, 2019 | Issued |
Array
(
[id] => 14310337
[patent_doc_number] => 20190144872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => Generating Targeted Sequence Diversity in Fusion Proteins
[patent_app_type] => utility
[patent_app_number] => 16/256507
[patent_app_country] => US
[patent_app_date] => 2019-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20734
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16256507
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/256507 | Generating targeted sequence diversity in fusion proteins | Jan 23, 2019 | Issued |
Array
(
[id] => 15254109
[patent_doc_number] => 20190375788
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE AND DISC TISSUE PATHOLOGIES
[patent_app_type] => utility
[patent_app_number] => 16/247003
[patent_app_country] => US
[patent_app_date] => 2019-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27464
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247003
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/247003 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE AND DISC TISSUE PATHOLOGIES | Jan 13, 2019 | Abandoned |
Array
(
[id] => 19274437
[patent_doc_number] => 12024548
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Rapid method for cloning and expression of cognate antibody variable gene segments
[patent_app_type] => utility
[patent_app_number] => 16/244909
[patent_app_country] => US
[patent_app_date] => 2019-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8977
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 219
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16244909
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/244909 | Rapid method for cloning and expression of cognate antibody variable gene segments | Jan 9, 2019 | Issued |
Array
(
[id] => 19903108
[patent_doc_number] => 12280092
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-22
[patent_title] => Reprogrammed T cell-like NK cells
[patent_app_type] => utility
[patent_app_number] => 16/767497
[patent_app_country] => US
[patent_app_date] => 2019-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6403
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767497
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/767497 | Reprogrammed T cell-like NK cells | Jan 3, 2019 | Issued |
Array
(
[id] => 16351869
[patent_doc_number] => 10792362
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-06
[patent_title] => Compositions and methods for efficient delivery of molecules to cells
[patent_app_type] => utility
[patent_app_number] => 16/230393
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 14340
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230393
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/230393 | Compositions and methods for efficient delivery of molecules to cells | Dec 20, 2018 | Issued |
Array
(
[id] => 15975611
[patent_doc_number] => 10668107
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-02
[patent_title] => Methods of transdifferentiation and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/203654
[patent_app_country] => US
[patent_app_date] => 2018-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 118
[patent_no_of_words] => 36023
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 296
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16203654
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/203654 | Methods of transdifferentiation and methods of use thereof | Nov 28, 2018 | Issued |
Array
(
[id] => 15571513
[patent_doc_number] => 10576115
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-03
[patent_title] => Oncolytic HSV vector
[patent_app_type] => utility
[patent_app_number] => 16/191141
[patent_app_country] => US
[patent_app_date] => 2018-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 27
[patent_no_of_words] => 13151
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16191141
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/191141 | Oncolytic HSV vector | Nov 13, 2018 | Issued |
Array
(
[id] => 16420635
[patent_doc_number] => 20200345833
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => REV-DEPENDENT LENTIVIRAL VACCINE PARTICLES FOR REDUCING VIRAL REBOUND AND VIRAL RESERVOIRS IN VIVO
[patent_app_type] => utility
[patent_app_number] => 16/758577
[patent_app_country] => US
[patent_app_date] => 2018-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758577
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/758577 | Rev-dependent lentiviral vaccine particles for reducing viral rebound and viral reservoirs in vivo | Oct 22, 2018 | Issued |
Array
(
[id] => 19425270
[patent_doc_number] => 12084673
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => Vectors for the treatment of Friedreich's ataxia
[patent_app_type] => utility
[patent_app_number] => 16/757263
[patent_app_country] => US
[patent_app_date] => 2018-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 10992
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757263
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/757263 | Vectors for the treatment of Friedreich's ataxia | Oct 16, 2018 | Issued |
Array
(
[id] => 18352559
[patent_doc_number] => 20230140670
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 16/651911
[patent_app_country] => US
[patent_app_date] => 2018-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -63
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16651911
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/651911 | FORMULATIONS | Sep 27, 2018 | Pending |
Array
(
[id] => 17029954
[patent_doc_number] => 11091760
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-17
[patent_title] => Recombinant virus products and methods for inhibition of expression of myotilin
[patent_app_type] => utility
[patent_app_number] => 16/144432
[patent_app_country] => US
[patent_app_date] => 2018-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 19
[patent_no_of_words] => 10570
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144432
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/144432 | Recombinant virus products and methods for inhibition of expression of myotilin | Sep 26, 2018 | Issued |
Array
(
[id] => 13790787
[patent_doc_number] => 20190008932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/137028
[patent_app_country] => US
[patent_app_date] => 2018-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31880
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137028
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/137028 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | Sep 19, 2018 | Abandoned |
Array
(
[id] => 13790785
[patent_doc_number] => 20190008931
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/136926
[patent_app_country] => US
[patent_app_date] => 2018-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31882
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136926
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/136926 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | Sep 19, 2018 | Abandoned |
Array
(
[id] => 13790789
[patent_doc_number] => 20190008933
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/137049
[patent_app_country] => US
[patent_app_date] => 2018-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31880
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137049
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/137049 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | Sep 19, 2018 | Abandoned |